Minitran 10 (Glyceryl Trinitrate)

Glyceryl trinitrate releases nitric oxide in the vascular wall, which activates soluble guanylate cyclase. This raises cyclic GMP levels, causing smooth‑muscle relaxation in veins and arteries, lowering cardiac preload and afterload, and ultimately decreasing myocardial oxygen demand.

The prescribed dose of Minitran 10 is determined by the treating physician based on the patient’s clinical condition, response, and tolerance. The patch is typically applied once daily, delivering 10 mg of glyceryl trinitrate over a 24‑hour period, but exact dosing instructions must come from a qualified prescriber.

Minitran 10 is classified as pregnancy category B1, indicating no evidence of fetal risk in animal studies, but human data are limited. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, and the decision must be made by a healthcare professional.

To order Minitran 10, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Minitran 10 provides continuous nitrate delivery via a transdermal patch, offering steadier plasma levels than short‑acting oral nitrates. Compared with beta‑blockers or calcium‑channel blockers, it primarily reduces preload and myocardial oxygen demand, making it useful when those agents are contraindicated or insufficient alone.

Store Minitran 10 at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the patch away from heat sources and do not expose it to extreme temperatures, which could affect drug stability.

The patch is applied to a clean, dry, hair‑free area of the upper torso or upper arm. Remove the backing, press the adhesive side firmly for several seconds, and rotate the site daily to minimize skin irritation. Follow the prescriber’s instructions for timing and removal.

Serious risks include severe hypotension, syncope, and rare allergic reactions such as rash or breathing difficulty. Patients should be instructed to rise slowly from sitting or lying positions, report any fainting episodes, and seek immediate medical attention if they experience signs of an allergic response.

Minitran 10 is contraindicated in patients with known hypersensitivity to glyceryl trinitrate or other nitrates, those with severe anemia, increased intracranial pressure, or uncontrolled hypotension. It should also be avoided in individuals concurrently using phosphodiesterase‑5 inhibitors due to the risk of profound blood pressure drops.